Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Guida

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Journal of Translational Medicine|June 3, 2014
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Tumori|July 7, 2023
Outcomes in patients with <i>BRAF</i><sup>V600</sup>-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinibMassimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeVanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
Frontiers in Oncology|November 25, 2021
Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From ItalySabino Strippoli, Annarita Fanizzi, Davide Quaresmini, et al.
Journal of Geriatric Oncology|January 14, 2020
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre studyLaura Ridolfi, Francesco De Rosa, Elisabetta Petracci, et al.
Frontiers in Medicine|November 11, 2024
Corrigendum: The molecular tumor board as a step in cancer patient management: a southern Italian experienceStefania Tommasi, Leonarda Maurmo, Alessandro Rizzo, et al.
Cancer Investigation|February 4, 2014
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access programPaolo Antonio Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Frontiers in Medicine|September 26, 2024
The molecular tumor board as a step in cancer patient management: a southern Italian experienceStefania Tommasi, Leonarda Maurmo, Alessandro Rizzo, et al.
Tumori|July 3, 2019
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)Maria Giuseppa Vitale, Sergio Bracarda, Laura Cosmai, et al.
Cancers|February 3, 2021
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) StudyMichele Guida, Nicola Bartolomeo, Pietro Quaglino, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Journal of Translational Medicine|June 3, 2014
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Tumori|July 7, 2023
Outcomes in patients with <i>BRAF</i><sup>V600</sup>-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinibMassimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeVanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
Frontiers in Oncology|November 25, 2021
Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From ItalySabino Strippoli, Annarita Fanizzi, Davide Quaresmini, et al.
Journal of Geriatric Oncology|January 14, 2020
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre studyLaura Ridolfi, Francesco De Rosa, Elisabetta Petracci, et al.
Frontiers in Medicine|November 11, 2024
Corrigendum: The molecular tumor board as a step in cancer patient management: a southern Italian experienceStefania Tommasi, Leonarda Maurmo, Alessandro Rizzo, et al.
Cancer Investigation|February 4, 2014
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access programPaolo Antonio Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Frontiers in Medicine|September 26, 2024
The molecular tumor board as a step in cancer patient management: a southern Italian experienceStefania Tommasi, Leonarda Maurmo, Alessandro Rizzo, et al.
Tumori|July 3, 2019
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)Maria Giuseppa Vitale, Sergio Bracarda, Laura Cosmai, et al.
Cancers|February 3, 2021
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) StudyMichele Guida, Nicola Bartolomeo, Pietro Quaglino, et al.
Pageof 13